Clinical trials: Non-cystic Fibrosis Bronchiectasis
Healthy Participants, Non-cystic Fibrosis Bronchiectasis
A Phase 1a/1b Study to Investigate the Safety, Tolerability, Microbiological Response, and Pharmacokinetics of Inhaled Rev-56 in Adult Healthy Volunteers and Adult Non-cystic Fibrosis Bronchiectasis (NCFB) Patients With Chronic P. Aeruginosa
This is a Phase 1a/1b study to test the safety, tolerability, microbiological response, and pharmacokinetics of inhaled Rev-56 compared to placebo in adult healthy participants and non-cystic fibrosis bronchiectasis (NCFB)…
- Trial name
- NCT07709494
- Testing
- Rev-56 for Inhalation
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Revagenix, Inc.
Non-cystic Fibrosis Bronchiectasis
The Role of Pulmonary Rehabilitation and Airways Clearance Techniques in the Multidisciplinary Management of Non CF Bronchiectasis
Pulmonary rehabilitation programs are part of the multidisciplinary treatment of some chronic respiratory diseases such as COPD (chronic obstructive pulmonary disease).
- Trial name
- NCT02614300
- Testing
- Pulmonary Rehabilitation and Chest Physiotherapy, Pulmonary Rehabilitation, Chest Physiotherapy
- Volunteers
- 120 people
- Sponsor
- Hospital Clinic of Barcelona
Bronchiectasis
Effects of Azithromycin on Airway Oxidative Stress Markers in Patients With Bronchiectasis
The mechanism by which macrolide antibiotics have immune modifying effects independent from its antibacterial activity has not been well established.
- Trial name
- NCT01463371
- Testing
- Azithromycin
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Instituto de Investigacion Sanitaria La Fe
Non-cystic Fibrosis Bronchiectasis (NCFBE)
Investigation of Pharmacokinetics, Safety of HSK31858 in Subjects With Hepatic Impairment
The study is being conducted to compare the pharmacokinetics, safety of HSK31858 in subjects with mild, moderate, severe hepatic impairment and normal hepatic function.
- Trial name
- NCT07913009
- Testing
- HSK31858 tablets
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Cystic Fibrosis (CF), Non Cystic Fibrosis Bronchiectasis
Feasibility and Acceptance of SonoHeal for Airway Clearance and Preliminary Comparison With the Standard of Care
The proposed study is to gauge the early feasibility and acceptance of the SonoHeal device. The study will evaluate the usability of the SonoHeal prototype using well-established Human Factors Engineering methods recommended by…
- Conditions
- Cystic Fibrosis (CF), Non Cystic Fibrosis Bronchiectasis, Chronic Obstructive Pulmonary Disease (COPD)
- Trial name
- NCT07568119
- Testing
- Airway clearance therapy through acoustic oscillations
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Cognita Labs LLC
Non-Cystic Fibrosis Bronchiectasis
A Multicenter, Randomized, Double-blind, Placebo-controlled Parallel-group Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of XH-S004 Tablets in Patients With Non-cystic Fibrosis Bronchiectasis
The purpose of this study is to find out if XH-S004 can reduce pulmanary exacerbation over a 24-week treatment duration in participants with non-cystic fibrosis bronchiectasis.
- Trial name
- NCT06981091
- Testing
- XH-S004 20 mg, XH-S004 40 mg
- Where
- China
- Volunteers
- 234 people
- Sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Non-cystic Fibrosis Bronchiectasis
A Study in Patients With Non-cystic Fibrosis Bronchiectasis to Test How Well Different Doses of BI 1323495 Are Tolerated and How BI 1323495 Affects Biomarkers of Inflammation
This study is open to adults with non-cystic fibrosis bronchiectasis. The main purpose of this study is to find out how a medicine called BI 1323495 is tolerated by people with non-cystic bronchiectasis.
- Trial name
- NCT04656275
- Testing
- BI 1323495
- Where
- 3 sites in Germany
- Volunteers
- 7 people
- Sponsor
- Boehringer Ingelheim
Bronchiectasis
Effects of Chest Physiotherapy (CPT) on Lung Clearance Index (LCI) in Non Cystic Fibrosis (CF) Bronchiectasis
This study will investigate the effects of on technique of chest physiotherapy on pulmonary function. Effects of pulmonary function will be measured by the spirometry, body plethysmography and by the multiple breath nitrogen…
- Trial name
- NCT02411981
- Testing
- Autogenic drainage
- Where
- Belgium
- Volunteers
- 24 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Non-Cystic Fibrosis Bronchiectasis
Assessment of INS1007 in Participants With Non-Cystic Fibrosis Bronchiectasis
The purpose of the study is to evaluate if INS1007 can reduce pulmonary exacerbations over a 24-week treatment period in participants with non-cystic fibrosis bronchiectasis.
- Trial name
- NCT03218917
- Testing
- Brensocatib 10 mg, Brensocatib 25 mg
- Where
- 108 sites in United States, Australia and 12 more
- Volunteers
- 256 people
- Sponsor
- Insmed Incorporated
Bronchiectasis, Sleep-Disordered Breathing
Sleep Quality in Patients With Non-cystic Fibrosis Bronchiectasis
Non-cystic fibrosis (non-CF) bronchiectasis is a chronic, heterogeneous airway disease characterized by irreversible bronchial dilatation, persistent airway infection, and neutrophilic inflammation that together drive daily…
- Trial name
- NCT07147803
- Testing
- Pittsburgh Sleep Quality Index
- Where
- Egypt
- Volunteers
- 200 people
- Sponsor
- Assiut University
Non-cystic Fibrosis Bronchiectasis
The Effects of Pulmonary Rehabilitation in Patients With Non-cystic Fibrosis Bronchiectasis
Number of Patients: Study group - Bronchiectasis that is not attributable to Cystic fibrosis Group 1 - Pulmonary Rehabilitation Group 2 - Standard care Sample size - 20 in each arm Study Design: Randomised controlled trial (RCT)…
- Trial name
- NCT02883101
- Testing
- Pulmonary Rehabilitation
- Where
- India
- Volunteers
- 60 people
- Sponsor
- All India Institute of Medical Sciences
Bronchiectasis
Exercise Capacity in Patients With Cystic Fibrosis vs. Non-cystic Fibrosis Bronchiectasis
Introduction: Bronchiectasis is a chronic lung disease in which the underlying condition causes permanent damage to the conducting airways. Bronchiectasis is associated with considerable morbidity and poor quality of life.
- Trial name
- NCT03147651
- Where
- Israel
- Volunteers
- 119 people
- Sponsor
- Rambam Health Care Campus
Non-Cystic Fibrosis Bronchiectasis
Nebulised RESP30X Nitric Oxide Formulations in NCFB Patients With Pseudomonas Aeruginosa (Pa)
A Phase 1/2a, Multi-Centre, Randomised, Open-label study to assess the safety, tolerability, PK, and efficacy of RESP30X in Adult NCFB participants with confirmed high-titre respiratory PPMs.
- Trial name
- NOPA (NCT06663176)
- Testing
- RESP302, RESP303
- Where
- Ukraine
- Volunteers
- 60 people
- Sponsor
- Thirty Respiratory Limited
Bronchiectasis
Vitamin D as an Adjunctive Treatment in Patients With Non-Cystic Fibrosis Bronchiectasis
This study evaluates vitamin D as an adjunctive treatment in patients with non-Cystic Fibrosis bronchiectasis, which are combined with vitamin D deficiency.
- Trial name
- VIDB (NCT02507843)
- Testing
- Cholecalciferol
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Non-cystic Fibrosis Bronchiectasis
Roflumilast in Non-CF Bronchiectasis Study (2019)
This is a single-arm, open label, Phase II study of 12-week use of Roflumilast in stable-state non-cystic fibrosis bronchiectasis subjects.
- Trial name
- NCT04322929
- Testing
- Roflumilast Oral Tablet
- Where
- Hong Kong
- Volunteers
- 42 people
- Sponsor
- The University of Hong Kong
Cystic Fibrosis, Non-Cystic Fibrosis Bronchiectasis
A Clinical Study to Investigate Safety, Tolerability and Distribution of CHF 6333 After One or After Repeated Inhalation in Patients With Cystic Fibrosis (CF) and in Patients With Non Cystic Fibrosis (NCFB) Bronchiectasis
CHF 6333 is a medicinal product on development for the treatment of cystic fibrosis and non-CF bronchiectasis and undergoing clinical testing. It has not yet been approved by the authorities for the treatment of these diseases.
- Trial name
- NCT04010799
- Testing
- CHF 6333
- Where
- Germany
- Volunteers
- 68 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Cystic Fibrosis (CF), Bronchiectasis, Non-Cystic Fibrosis
Diagnostic Value of Oropharyngeal Suction and Effect of Respiratory Physiotherapy on the Detection of Microorganisms in the Pediatric Patient
The goal of this clinical trial is to determine the effectiveness of oropharyngeal suction in detecting microorganisms by comparing it with induced sputum and oropharyngeal swab samples.
- Trial name
- NCT07903792
- Testing
- Respiratory physiothperapy, Oropharyngeal suction, Oropharyngeal swab
- Where
- Spain
- Volunteers
- 196 people
- Sponsor
- Corporacion Parc Tauli
Bronchiectasis
The Long Term Effect of Inhaled Hypertonic Saline (6%) in Patients With Non Cystic Fibrosis Bronchiectasis
The purpose of this study is to determine whether the daily inhalation of nebulised hypertonic saline (6%) will decrease the incidence of pulmonary exacerbations and increase the quality of life for people with non cystic…
- Trial name
- NCT00484263
- Testing
- Hypertonic saline 6% -
- Where
- Australia
- Volunteers
- 40 people
- Sponsor
- The Alfred
Bronchiectasis Adult
Effect of Long Term Clarithromycin for Prevention of Exacerbations in Non-cystic Fibrosis Bronchiectasis in Asian Populations
clarithromycin may reduce the exacerbations in middle-aged and elderly patients with non-CF bronchiectasis. The study is aimed to (A) investigate the etiologies and clinical features of patients with bronchiectasis, (B) compare…
- Trial name
- NCT04658277
- Testing
- Clarithromycin, Usual care
- Where
- Hong Kong
- Volunteers
- 40 people
- Sponsor
- Chinese University of Hong Kong
Bronchiectasis
Long Term Nebulised Gentamicin in Patients With Bronchiectasis
The hypothesis of this randomized placebo controlled trial is that targeted nebulized gentamicin to the airways will reduce bacterial burden and limit neutrophil airways inflammation.
- Trial name
- NCT00749866
- Testing
- Gentamicin, Saline
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- University of Edinburgh